(Q39743972)

14 September 2017

title

Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians (English)

1 reference

14 September 2017

0 references

2

Julian Little

1 reference

14 September 2017

8

Kumanan Wilson

1 reference

14 September 2017

Beth K Potter

1

1 reference

14 September 2017

Pranesh Chakraborty

3

1 reference

14 September 2017

Jonathan B Kronick

4

1 reference

14 September 2017

Jessica Evans

5

1 reference

14 September 2017

Julia Frei

6

1 reference

14 September 2017

Sarah C Sutherland

7

1 reference

14 September 2017

Brenda J Wilson

9

1 reference

14 September 2017

publication date

1 June 2011

1 reference

Journal of Inherited Metabolic Disease

14 September 2017

published in

1 reference

14 September 2017

volume

35

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

115-123

1 reference

A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Potential of fibrates in the treatment of fatty acid oxidation disorders: Revival of classical drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Clinical research for rare disease: opportunities, challenges, and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Komrower lecture: Treatment of inborn errors of metabolism: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Choice of oils for essential fat supplements can enhance production of abnormal metabolites in fat oxidation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Management of Fatty Acid Oxidation Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Current issues regarding treatment of mitochondrial fatty acid oxidation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Methodologies for improving response rates in surveys of physicians: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

L-carnitine in inborn errors of metabolism: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Fatty acid oxidation disorders: outcome and long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9352-2

Management of fatty acid oxidation disorders: a survey of current treatment strategies

21 January 2018

1 reference

12 December 2020

Patient-Centered Outcomes Research Institute: the intersection of science and health care

1 reference

12 December 2020

Long-term follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services' Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children

1 reference

12 December 2020

Clinical trials: curing a critical deficiency in metabolic medicine

1 reference

12 December 2020

Evidence based medicine in inborn errors of metabolism: is there any and how to find it

1 reference

12 December 2020

Carnitine supplementation for inborn errors of metabolism

1 reference

12 December 2020

10.1007/S10545-011-9352-2

Identifiers

DOI

1 reference

14 September 2017

1 reference